Celmatix Company

Celmatix is a next-generation women’s health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions. Their products include Polaris, Fertilome genetic test and MyFertility Compass. Polaris is a web-based platform to help optimize patient management. It features Polaris Treatment Navigator - a visual counseling tool that complements a physician’s treatment recommendation and leverages powerful predictive models to provide an immediate “second opinion”. The Fertilome genetic test reveals genetic risk factors related to reproductive conditions that may affect a woman's ability to conceive. MyFertility Compass estimates the woman's chances of getting pregnant. The projections behind MyFertility Compass are based on women who are trying to get pregnant with a male partner, with or without the help of a doctor.
Technology: Biotechnology, Fertility, Genetics, Health Care
Industry: Longevity
Headquarters: New York, New York, United States
Founded Date: 2009
Employees Number: 101-250
Funding Status: Early Stage Venture

Visit Website
twitter.com/celmatix
Register and Claim Ownership